Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Equity Average (2016 - 2025)

Enanta Pharmaceuticals' Equity Average history spans 13 years, with the latest figure at $95.7 million for Q4 2025.

  • For Q4 2025, Equity Average fell 20.5% year-over-year to $95.7 million; the TTM value through Dec 2025 reached $95.7 million, down 20.5%, while the annual FY2025 figure was $96.8 million, 43.99% down from the prior year.
  • Equity Average reached $95.7 million in Q4 2025 per ENTA's latest filing, up from $72.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $444.0 million in Q1 2021 to a low of $72.0 million in Q3 2025.
  • Average Equity Average over 5 years is $247.7 million, with a median of $240.4 million recorded in 2023.
  • Peak YoY movement for Equity Average: fell 8.29% in 2021, then tumbled 48.15% in 2025.
  • A 5-year view of Equity Average shows it stood at $391.9 million in 2021, then dropped by 20.62% to $311.1 million in 2022, then plummeted by 34.32% to $204.3 million in 2023, then crashed by 41.11% to $120.3 million in 2024, then decreased by 20.5% to $95.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Equity Average are $95.7 million (Q4 2025), $72.0 million (Q3 2025), and $86.4 million (Q2 2025).